Patients With High-grade Pancreatic Neuroendocrine Tumors

* Pancreatic neuroendocrine tumor (pNET) is a rare form of cancer. Treatment options such as hormonal therapy (octreotide) and targeted therapy (everolimus and sunitinib) may be considered for grade 1 or 2 pNETs; however, cytotoxic chemotherapy is essential in cases with grade 3 pNETs or pNECs. * Cisplatin/etoposide remains the treatment of choice for high-grade pNET/pNEC. Other irinotecan-based therapies, such as FOLFIRI (cisplatin/irinotecan), FOLFOX, and temozolomide ± capecitabine, have been employed; however, a standard of care remains to be established.

NCT Number	NCT07121478
Lead Sponsor	National Cancer Center, Korea Collaborators: Seoul National University Bundang Hospital, Samsung Medical Center, Seoul National Hospital, Gangnam Severance Hospital
Conditions	Neuroendocrine Tumor of Pancreas, Pancreatic Neuroendocrine Tumors
Enrollment	46 participants
Start Date	2025-09-23
Primary Completion	2027-03-01 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-10-01